Husain H, et al. JCOPO. 2022. DOI123456789
Background:
Professional guidelines recommend genomic testing in multiple cancer types; however, many patients receive limited or no biomarker testing.[1,2] Liquid biopsy (LBx) is a pragmatic and accessible option for comprehensive genomic profiling (CGP) that detects actionable alterations to inform treatment decisions and promote guideline-adherent care.[2] Liquid biopsy sensitivity varies based on the amount of circulating tumor DNA (ctDNA) in the blood.[1] Professional guidelines recommend reflex to tissue biopsy when liquid biopsy is negative.[2] Tumor fraction (TF) is a biomarker measuring ctDNA abundance in a sample; this study evaluated the relationship between TF and biomarker detection.[1,3]
Study Details:
23,482 samples representing 25 solid tumor types were profiled using FoundationOne®Liquid CDx and analyzed retrospectively. ctDNA shed was quantified using a proprietary algorithm to determine a composite TF value. Tissue (TBx) and LBx concordance was analyzed on samples for non-small cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer samples where liquid CGP was conducted within 0-5 years of tissue CGP. Sensitivity (positive percent agreement and negative predictive value) were evaluated.[1]
Why this matters:
This study found that TF is a key determinant of LBx performance and can be used to prioritize when a reflex to tissue may be beneficial for a given patient.
View the full publication on ascopubs.org.
References
[1]Husain H, et al. JCOPO. 2022. DOI123456789
[2]Rolfo C, et al. J Thoracic Oncol. 2021. 2021;16(10):1647-1662.3.
[3]Huang RSP, et al. Clin Chem. 2021;67(11):1554-1566.